Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Return on Sales (2016 - 2025)

Vanda Pharmaceuticals' Return on Sales history spans 16 years, with the latest figure at 0.02% for Q4 2025.

  • On a quarterly basis, Return on Sales fell 2.0% to 0.02% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.01%, a 1.0% decrease, with the full-year FY2025 number at 0.01%, down 1.0% from a year prior.
  • Return on Sales hit 0.02% in Q4 2025 for Vanda Pharmaceuticals, down from 0.0% in the prior quarter.
  • Over the last five years, Return on Sales for VNDA hit a ceiling of 0.0% in Q2 2021 and a floor of 0.02% in Q4 2025.
  • Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2023.
  • Biggest five-year swings in Return on Sales: changed 0bps in 2021 and later decreased -2bps in 2025.
  • Tracing VNDA's Return on Sales over 5 years: stood at 0.0% in 2021, then grew by 2bps to 0.0% in 2022, then crashed by -150bps to 0.0% in 2023, then tumbled by -73bps to 0.0% in 2024, then plummeted by -2592bps to 0.02% in 2025.
  • Business Quant data shows Return on Sales for VNDA at 0.02% in Q4 2025, 0.0% in Q3 2025, and 0.01% in Q2 2025.